Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 143

1.

MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis.

Bonneville F, Rivière LD, Petersenn S, Bevan J, Houchard A, Sert C, Caron PJ.

Eur J Endocrinol. 2018 Dec 1. pii: EJE-18-0254.R2. doi: 10.1530/EJE-18-0254. [Epub ahead of print]

PMID:
30540560
2.

Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic steps.

Koch CA, Petersenn S.

Rev Endocr Metab Disord. 2018 Jun;19(2):107-109. doi: 10.1007/s11154-018-9472-1. No abstract available.

PMID:
30357544
3.

Black swans - neuroendocrine tumors of rare locations.

Koch CA, Petersenn S.

Rev Endocr Metab Disord. 2018 Jun;19(2):111-121. doi: 10.1007/s11154-018-9473-0. Review.

PMID:
30341705
4.

Aggressive pituitary tumours and carcinomas: two sides of the same coin?

Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, Raverot G.

Eur J Endocrinol. 2018 Jun;178(6):C7-C9. doi: 10.1530/EJE-18-0250. Epub 2018 Mar 27. Review.

PMID:
29588294
5.

Secondary adrenal insufficiency in pregnancy: any differences?

Petersenn S.

Minerva Endocrinol. 2018 Dec;43(4):446-450. doi: 10.23736/S0391-1977.18.02840-7. Epub 2018 Mar 15.

PMID:
29546743
6.

Pituitary disease management during pregnancy: an overview.

Petersenn S.

Minerva Endocrinol. 2018 Dec;43(4):420-422. doi: 10.23736/S0391-1977.18.02835-3. Epub 2018 Mar 15. No abstract available.

7.

Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Petersenn S, Koch CA.

Rev Endocr Metab Disord. 2017 Dec;18(4):373-378. doi: 10.1007/s11154-018-9442-7. No abstract available.

PMID:
29480376
8.

Editorial : Neuroendocrine neoplasms.

Koch CA, Petersenn S.

Rev Endocr Metab Disord. 2017 Dec;18(4):379-380. doi: 10.1007/s11154-018-9441-8. No abstract available.

PMID:
29417306
9.

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.

McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P; ESE survey collaborators.

Eur J Endocrinol. 2018 Mar;178(3):265-276. doi: 10.1530/EJE-17-0933. Epub 2018 Jan 12.

PMID:
29330228
10.

Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.

Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, Schirbel A, Deutschbein T, Williams TA, Rhayem Y, Quinkler M, Rayes N, Monticone S, Wild V, Gomez-Sanchez CE, Reis AC, Petersenn S, Wester HJ, Kropf S, Fassnacht M, Lang K, Herrmann K, Buck AK, Bluemel C, Hahner S.

Hypertension. 2018 Feb;71(2):317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975. Epub 2017 Dec 26.

11.

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM; European Society of Endocrinology.

Eur J Endocrinol. 2018 Jan;178(1):G1-G24. doi: 10.1530/EJE-17-0796. Epub 2017 Oct 18. Review.

PMID:
29046323
12.

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.

Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J; Pasireotide G2304 Study Group.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12. Erratum in: Lancet Diabetes Endocrinol. 2018 Jan;6(1):e1.

PMID:
29032078
13.

[Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

Petersenn S, Christ-Crain M, Droste M, Finke R, Flitsch J, Kreitschmann-Andermahr I, Luger A, Schopohl J, Stalla G.

Internist (Berl). 2017 Nov;58(11):1171-1182. doi: 10.1007/s00108-017-0331-z. Review. German.

PMID:
29027568
14.

Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.

Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BMK.

Endocrine. 2017 Jul;57(1):156-165. doi: 10.1007/s12020-017-1316-3. Epub 2017 Jun 9.

15.

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.

Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, Lanza V, Söderkvist P, Stenman A, Larsson C, Svahn F, Chen JL, Marquard J, Fraenkel M, Walter MA, Peczkowska M, Prejbisz A, Jarzab B, Hasse-Lazar K, Petersenn S, Moeller LC, Meyer A, Reisch N, Trupka A, Brase C, Galiano M, Preuss SF, Kwok P, Lendvai N, Berisha G, Makay Ö, Boedeker CC, Weryha G, Racz K, Januszewicz A, Walz MK, Gimm O, Opocher G, Eng C, Neumann HPH; European-American-Asian Pheochromocytoma-Paraganglioma Registry Study Group.

JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223.

16.

National German Audit of Diagnosis, Treatment, and Teaching in Secondary Adrenal Insufficiency.

Petersenn S, Honegger J, Quinkler M.

Horm Metab Res. 2017 Aug;49(8):580-588. doi: 10.1055/s-0043-105077. Epub 2017 Mar 28.

PMID:
28351092
17.

Anthropometric factors have significant influence on the outcome of the GHRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone.

Deutschbein T, Bidlingmaier M, Schopohl J, Strasburger CJ, Petersenn S.

Eur J Endocrinol. 2017 Mar;176(3):273-281. doi: 10.1530/EJE-16-0668. Epub 2016 Dec 8.

PMID:
27932410
18.

Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.

Caron PJ, Petersenn S, Houchard A, Sert C, Bevan JS; PRIMARYS Study Group.

Clin Endocrinol (Oxf). 2017 Apr;86(4):541-551. doi: 10.1111/cen.13285. Epub 2016 Dec 27.

PMID:
27874199
19.

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM.

Endocrine. 2016 Nov;54(2):516-523. Epub 2016 May 21.

20.

Health-related Quality of Life in Patients After Treatment of Cushing's Disease.

Nader S, Burkhardt T, Vettorazzi E, Milian M, Aberle J, Petersenn S, Flitsch J.

Exp Clin Endocrinol Diabetes. 2016 Mar;124(3):187-91. doi: 10.1055/s-0035-1569340. Epub 2016 Mar 23.

PMID:
27008635
21.

Erratum: Histological criteria for atypical pituitary adenomas--data from the German pituitary adenoma registry suggests modifications.

Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, Bergmann M, Knappe UJ, Hans VH, Flitsch J, Saeger W, Buslei R.

Acta Neuropathol Commun. 2016 Feb 29;4:21. doi: 10.1186/s40478-016-0290-y.

22.

Emerging Histopathological and Genetic Parameters of Pituitary Adenomas: Clinical Impact and Recommendation for Future WHO Classification.

Saeger W, Petersenn S, Schöfl C, Knappe UJ, Theodoropoulou M, Buslei R, Honegger J.

Endocr Pathol. 2016 Jun;27(2):115-22. doi: 10.1007/s12022-016-9419-6. Review.

PMID:
26874696
23.

Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schöfl C, Petersenn S, Buslei R.

Endocr Pathol. 2016 Jun;27(2):104-14. doi: 10.1007/s12022-016-9418-7. Review.

PMID:
26860936
24.

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.

Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM; PRIMARYS Investigators Group.

Pituitary. 2016 Apr;19(2):149-57. doi: 10.1007/s11102-015-0693-y.

25.

How to manage pasireotide, when using as medical treatment for Cushing's disease.

Petersenn S.

Endocrine. 2015 Dec;50(3):526-8. doi: 10.1007/s12020-015-0754-z. Epub 2015 Sep 29. No abstract available.

PMID:
26419848
26.

SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study.

Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S; SAGIT Investigator Group.

Pituitary. 2016 Feb;19(1):39-49. doi: 10.1007/s11102-015-0681-2.

27.

Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, Bergmann M, Knappe HU, Hans VH, Flitsch J, Saeger W, Buslei R.

Acta Neuropathol Commun. 2015 Aug 19;3:50. doi: 10.1186/s40478-015-0229-8. Erratum in: Acta Neuropathol Commun. 2016;4(1):21.

28.

Diagnosis of Primary Hypophysitis in Germany.

Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, Strasburger C, Störmann S, Küppers A, Streetz-van der Werf C, Deutschbein T, Stieg M, Rotermund R, Milian M, Petersenn S; Pituitary Working Group of the German Society of Endocrinology.

J Clin Endocrinol Metab. 2015 Oct;100(10):3841-9. doi: 10.1210/jc.2015-2152. Epub 2015 Aug 11.

PMID:
26262437
29.

Treatment of Primary Hypophysitis in Germany.

Honegger J, Buchfelder M, Schlaffer S, Droste M, Werner S, Strasburger C, Störmann S, Schopohl J, Kacheva S, Deutschbein T, Stalla G, Flitsch J, Milian M, Petersenn S, Elbelt U; Pituitary Working Group of the German Society of Endocrinology.

J Clin Endocrinol Metab. 2015 Sep;100(9):3460-9. doi: 10.1210/jc.2015-2146. Epub 2015 Jun 19.

PMID:
26091204
30.

Cushing disease: where do we stand, where are we heading?

Fleseriu M, Petersenn S.

Pituitary. 2015 Apr;18(2):179-80. doi: 10.1007/s11102-015-0647-4. No abstract available.

PMID:
25759331
31.

Pituitary-directed medical therapy in Cushing's disease.

Petersenn S, Fleseriu M.

Pituitary. 2015 Apr;18(2):238-44. doi: 10.1007/s11102-015-0639-4. Review.

PMID:
25627118
32.

Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence.

Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M, Brue T, Bruzzi P, Casanueva FF, Chanson P, Colao A, Reincke M, Stalla G, Tsagarakis S.

Eur J Endocrinol. 2015 Jun;172(6):R227-39. doi: 10.1530/EJE-14-0883. Epub 2015 Jan 19. Review.

PMID:
25599709
33.

Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry.

Petersenn S, Richter PA, Broemel T, Ritter CO, Deutschbein T, Beil FU, Allolio B, Fassnacht M; German ACC Study Group.

Eur J Endocrinol. 2015 Apr;172(4):415-22. doi: 10.1530/EJE-14-0916. Epub 2015 Jan 19.

PMID:
25599706
34.

Total Testosterone and Calculated Estimates for Free and Bioavailable Testosterone: Influence of Age and Body Mass Index and Establishment of Sex-Specific Reference Ranges.

Deutschbein T, Mann K, Petersenn S.

Horm Metab Res. 2015 Oct;47(11):846-54. doi: 10.1055/s-0034-1395569. Epub 2015 Jan 7.

PMID:
25565093
35.

Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.

Fleseriu M, Petersenn S.

Pituitary. 2015 Apr;18(2):245-52. doi: 10.1007/s11102-014-0627-0. Review.

PMID:
25560275
36.

Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice.

Giustina A, Bevan J, Bronstein M, Casanueva F, Chanson P, Petersenn S, Truong TX, Massien C, Dias-Barbosa C, Guillemin I, Arnould B, Melmed S.

Value Health. 2014 Nov;17(7):A355. doi: 10.1016/j.jval.2014.08.754. Epub 2014 Oct 26. No abstract available.

37.

Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.

Deutschbein T, Fassnacht M, Weismann D, Reincke M, Mann K, Petersenn S.

Clin Endocrinol (Oxf). 2015 Jan;82(1):84-90. doi: 10.1111/cen.12590. Epub 2014 Oct 24.

PMID:
25143180
38.

Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas.

Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, Petersenn S.

Horm Metab Res. 2014 Aug;46(9):644-50. doi: 10.1055/s-0034-1383566. Epub 2014 Aug 15.

PMID:
25126861
39.

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.

Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A.

J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24.

PMID:
24800725
40.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27.

PMID:
24533697
41.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, Maisonobe P, Clermont A; PRIMARYS Investigators.

J Clin Endocrinol Metab. 2014 Apr;99(4):1282-90. doi: 10.1210/jc.2013-3318. Epub 2013 Jan 1.

42.

Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.

Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM.

Pituitary. 2014 Aug;17(4):320-6. doi: 10.1007/s11102-013-0503-3.

43.

High variability in baseline urinary free cortisol values in patients with Cushing's disease.

Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM; Pasireotide B2305 Study Group.

Clin Endocrinol (Oxf). 2014 Feb;80(2):261-9. doi: 10.1111/cen.12259. Epub 2013 Jul 15.

44.

New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.

Fleseriu M, Petersenn S.

J Neurooncol. 2013 Aug;114(1):1-11. doi: 10.1007/s11060-013-1151-1. Epub 2013 May 15. Review.

45.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.

Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Reséndiz K, Hughes G, Hu K, Barkan A.

Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0. Erratum in: Pituitary. 2014 Apr;17(2):141. Block, Christophe [corrected to De Block, Christophe].

46.

Screening for Cushing's syndrome: new immunoassays require adequate normative data.

Deutschbein T, Petersenn S.

Horm Metab Res. 2013 Feb;45(2):118-23. doi: 10.1055/s-0032-1331745. Epub 2013 Feb 15. Review.

PMID:
23417245
47.

Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population.

Berg C, Petersenn S, Walensi M, Möhlenkamp S, Bauer M, Lehmann N, Roggenbuck U, Moebus S, Broecker-Preuss M, Sandalcioglu IE, Stolke D, Sure U, Joeckel KH, Erbel R, Führer D, Mann K; Investigative Group of the Heinz Nixdorf Recall Study.

Exp Clin Endocrinol Diabetes. 2013 Feb;121(2):125-32. doi: 10.1055/s-0032-1314811. Epub 2013 Jan 21.

PMID:
23338744
48.

Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues.

Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S.

Exp Clin Endocrinol Diabetes. 2012 Sep;120(8):482-9. doi: 10.1055/s-0032-1314859. Epub 2012 Sep 13.

PMID:
22976314
49.

Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency.

Benson S, Neumann P, Unger N, Schedlowski M, Mann K, Elsenbruch S, Petersenn S.

Eur J Endocrinol. 2012 Nov;167(5):679-85. doi: 10.1530/EJE-12-0351. Epub 2012 Aug 28.

PMID:
22930487
50.

Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18.

PMID:
22918768
51.

Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.

Manolopoulou J, Alami Y, Petersenn S, Schopohl J, Wu Z, Strasburger CJ, Bidlingmaier M.

Clin Chem. 2012 Oct;58(10):1446-56. Epub 2012 Aug 20.

52.

Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass.

Unger N, Hinrichs J, Deutschbein T, Schmidt H, Walz MK, Mann K, Petersenn S.

Exp Clin Endocrinol Diabetes. 2012 Sep;120(8):494-500. doi: 10.1055/s-0032-1309007. Epub 2012 Jun 13.

PMID:
22696168
53.

Medical management of Cushing's disease: what is the future?

Fleseriu M, Petersenn S.

Pituitary. 2012 Sep;15(3):330-41. doi: 10.1007/s11102-012-0397-5. Review.

54.

A 12-month phase 3 study of pasireotide in Cushing's disease.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group.

N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.

PMID:
22397653
55.

Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.

Petersenn S, Hu K, Maldonado M, Zhang Y, Lasher J, Bouillaud E, Wang Y, Mann K, Unger N.

Clin Ther. 2012 Mar;34(3):677-88. doi: 10.1016/j.clinthera.2012.01.015. Epub 2012 Feb 24.

PMID:
22364824
56.

Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas.

Müssig K, Wehrmann T, Dittmann H, Wehrmann M, Ueberberg B, Schulz S, Bares R, Petersenn S.

Clin Endocrinol (Oxf). 2012 Jul;77(1):139-45. doi: 10.1111/j.1365-2265.2012.04343.x.

PMID:
22248072
57.

Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay.

Deutschbein T, Broecker-Preuss M, Flitsch J, Jaeger A, Althoff R, Walz MK, Mann K, Petersenn S.

Eur J Endocrinol. 2012 Apr;166(4):613-8. doi: 10.1530/EJE-11-0945. Epub 2012 Jan 3.

PMID:
22214924
58.

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.

59.

Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a single-center experience.

Deutschbein T, Unger N, Yuece A, Eberhardt W, Gauler T, Lahner H, Mann K, Petersenn S.

Horm Metab Res. 2011 Nov;43(12):838-43. doi: 10.1055/s-0031-1284354. Epub 2011 Oct 11.

PMID:
21989555
60.

Measurement of urinary free cortisol by current immunoassays: need for sex-dependent reference ranges to define hypercortisolism.

Deutschbein T, Broecker-Preuss M, Hartmann MF, Althoff R, Wudy SA, Mann K, Petersenn S.

Horm Metab Res. 2011 Sep;43(10):714-9. doi: 10.1055/s-0031-1286297. Epub 2011 Sep 19.

PMID:
21932176
61.

Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.

Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K.

J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14.

PMID:
21673137
62.

Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience.

Deutschbein T, Matuszczyk A, Moeller LC, Unger N, Yuece A, Lahner H, Mann K, Petersenn S.

Exp Clin Endocrinol Diabetes. 2011 Oct;119(9):540-3. doi: 10.1055/s-0031-1279704. Epub 2011 Jun 10.

PMID:
21667440
63.

68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax.

Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1224-36. doi: 10.1007/s00259-011-1760-x. Epub 2011 Mar 3.

PMID:
21369945
64.

Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M, Plöckinger U, Petersenn S; German Lanreotide Study Group.

Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):156-62. doi: 10.1055/s-0030-1267244. Epub 2010 Nov 17.

PMID:
21086246
65.

Monitoring medical treatment in adolescents and young adults with congenital adrenal hyperplasia: utility of salivary 17α-hydroxyprogesterone day profiles.

Deutschbein T, Unger N, Hauffa BP, Schaaf K, Mann K, Petersenn S.

Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):131-8. doi: 10.1055/s-0030-1255104. Epub 2010 Aug 5.

PMID:
20690075
66.

Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.

Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B; German ACC Registry Group.

J Clin Endocrinol Metab. 2010 Nov;95(11):4925-32. doi: 10.1210/jc.2010-0803. Epub 2010 Jul 28.

PMID:
20668036
67.

The rational use of pituitary stimulation tests.

Petersenn S, Quabbe HJ, Schöfl C, Stalla GK, von Werder K, Buchfelder M.

Dtsch Arztebl Int. 2010 Jun;107(25):437-43. doi: 10.3238/arztebl.2010.0437. Epub 2010 Jun 25. Review.

68.

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M.

BMC Endocr Disord. 2010 May 17;10:10. doi: 10.1186/1472-6823-10-10.

69.

Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.

Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K; Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators.

J Clin Endocrinol Metab. 2010 Aug;95(8):3648-56. doi: 10.1210/jc.2009-2570. Epub 2010 May 12.

PMID:
20463098
70.

Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.

Müssig K, Oksüz MO, Dudziak K, Ueberberg B, Wehrmann M, Horger M, Schulz S, Häring HU, Pfannenberg C, Bares R, Gallwitz B, Petersenn S.

Horm Metab Res. 2010 Jul;42(8):599-606. doi: 10.1055/s-0030-1253354. Epub 2010 Apr 26.

PMID:
20422506
71.

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group.

J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21.

PMID:
20410233
72.

[Arterial hypertension and subclinical Cushing's syndrome].

Fassnacht M, Beuschlein F, Quinkler M, Petersenn S.

MMW Fortschr Med. 2010 Feb 18;152(7):39-41. German. No abstract available.

PMID:
20364508
73.

[Pheochromocytoma: current diagnostics and treatment].

Quinkler M, Fassnacht M, Petersenn S, Reisch N, Willenberg HS, Diederich S.

MMW Fortschr Med. 2010 Feb 18;152(7):36-8. German. No abstract available.

PMID:
20364507
74.
75.

Posterior retroperitoneoscopic adrenalectomy for clinical and subclinical Cushing's syndrome.

Alesina PF, Hommeltenberg S, Meier B, Petersenn S, Lahner H, Schmid KW, Mann K, Walz MK.

World J Surg. 2010 Jun;34(6):1391-7. doi: 10.1007/s00268-010-0453-0.

PMID:
20143066
76.

Rationale for treatment and therapeutic options in Cushing's disease.

Stewart PM, Petersenn S.

Best Pract Res Clin Endocrinol Metab. 2009 Dec;23 Suppl 1:S15-22. doi: 10.1016/S1521-690X(09)70004-1. Review.

PMID:
20129190
77.

Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma.

Deutschbein T, Unger N, Jaeger A, Broecker-Preuss M, Mann K, Petersenn S.

Clin Endocrinol (Oxf). 2010 Aug;73(2):153-60. doi: 10.1111/j.1365-2265.2009.03761.x. Epub 2009 Dec 18.

PMID:
20039892
78.

Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery.

Berg C, Meinel T, Lahner H, Yuece A, Mann K, Petersenn S.

Eur J Endocrinol. 2010 Mar;162(3):477-82. doi: 10.1530/EJE-09-0824. Epub 2009 Dec 8.

PMID:
19996199
79.

Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.

Alaioubi B, Mann K, Petersenn S.

Horm Metab Res. 2010 Mar;42(3):198-203. doi: 10.1055/s-0029-1243184. Epub 2009 Nov 27.

PMID:
19946832
80.

Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients.

Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, Müssig K, Muresan M, Schäffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Plöckinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz MK, Eng C, Neumann HP; European-American Pheochromocytoma Study Group.

Clin Cancer Res. 2009 Oct 15;15(20):6378-85. doi: 10.1158/1078-0432.CCR-09-1237. Epub 2009 Oct 13.

81.

Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia.

Müssig K, Oksüz MO, Pfannenberg C, Adam P, Zustin J, Beckert S, Petersenn S.

J Clin Endocrinol Metab. 2009 Nov;94(11):4123-4. doi: 10.1210/jc.2009-0927. Epub 2009 Sep 29. No abstract available.

PMID:
19789203
82.

Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium.

Matuszczyk A, Petersenn S, Voigt W, Kegel T, Dralle H, Schmoll HJ, Bockisch A, Mann K.

Horm Metab Res. 2010 Jan;42(1):61-4. doi: 10.1055/s-0029-1238294. Epub 2009 Sep 4.

PMID:
19735058
83.

Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas.

Deutschbein T, Unger N, Hinrichs J, Walz MK, Mann K, Petersenn S.

Eur J Endocrinol. 2009 Nov;161(5):747-53. doi: 10.1530/EJE-09-0517. Epub 2009 Sep 2.

PMID:
19726566
84.

Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.

Ziegler CG, Brown JW, Schally AV, Erler A, Gebauer L, Treszl A, Young L, Fishman LM, Engel JB, Willenberg HS, Petersenn S, Eisenhofer G, Ehrhart-Bornstein M, Bornstein SR.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15879-84. doi: 10.1073/pnas.0907843106. Epub 2009 Aug 27.

85.

Expression of ghrelin and its receptor in human tissues.

Ueberberg B, Unger N, Saeger W, Mann K, Petersenn S.

Horm Metab Res. 2009 Nov;41(11):814-21. doi: 10.1055/s-0029-1233462. Epub 2009 Aug 10.

PMID:
19670151
86.

Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test.

Deutschbein T, Unger N, Mann K, Petersenn S.

Horm Metab Res. 2009 Nov;41(11):834-9. doi: 10.1055/s-0029-1225630. Epub 2009 Jul 7.

PMID:
19585406
87.

The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas.

Unger N, Deutschbein T, Walz MK, Mann K, Petersenn S.

Horm Metab Res. 2009 Sep;41(9):676-9. doi: 10.1055/s-0029-1224133. Epub 2009 Jun 25.

PMID:
19557670
88.

Saliva as a medium for aldosterone measurement in repeated sampling studies.

Manolopoulou J, Mulatero P, Maser-Gluth C, Rossignol P, Spyroglou A, Vakrilova Y, Petersenn S, Zwermann O, Plouin PF, Reincke M, Bidlingmaier M.

Steroids. 2009 Oct;74(10-11):853-8. doi: 10.1016/j.steroids.2009.05.006. Epub 2009 May 27.

PMID:
19481102
89.

The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes.

Garcia EA, King P, Sidhu K, Ohgusu H, Walley A, Lecoeur C, Gueorguiev M, Khalaf S, Davies D, Grossman AB, Kojima M, Petersenn S, Froguel P, Korbonits M.

Eur J Endocrinol. 2009 Aug;161(2):307-15. doi: 10.1530/EJE-09-0122. Epub 2009 May 21.

PMID:
19460888
90.

Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register.

Petersenn S, Buchfelder M, Gerbert B, Franz H, Quabbe HJ, Schulte HM, Grussendorf M, Reincke M; Participants of the German Acromegaly Register.

Clin Endocrinol (Oxf). 2009 Sep;71(3):400-5. doi: 10.1111/j.1365-2265.2009.03547.x. Epub 2009 Feb 18.

PMID:
19226273
91.

GH treatment reduces total ghrelin in Prader-Willi syndrome (PWS) and may confound ghrelin studies in young PWS children.

Hauffa BP, Petersenn S.

Clin Endocrinol (Oxf). 2009 Jul;71(1):155-6. doi: 10.1111/j.1365-2265.2008.03454.x. Epub 2008 Oct 20. No abstract available.

PMID:
19178506
92.

Diagnosis of growth hormone deficiency in adults: provocative testing with GHRP6 in comparison to the insulin tolerance test.

Alaioubi B, Mann K, Petersenn S.

Horm Metab Res. 2009 Mar;41(3):238-43. doi: 10.1055/s-0028-1093350. Epub 2008 Nov 12.

PMID:
19006049
93.

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J.

J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28.

PMID:
18957506
94.

Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test.

Deutschbein T, Unger N, Mann K, Petersenn S.

Eur J Endocrinol. 2009 Jan;160(1):9-16. doi: 10.1530/EJE-08-0600. Epub 2008 Oct 24.

PMID:
18952762
95.

Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation.

Arbeiter AK, Büscher R, Petersenn S, Hauffa BP, Mann K, Hoyer PF.

Nephrol Dial Transplant. 2009 Feb;24(2):643-6. doi: 10.1093/ndt/gfn529. Epub 2008 Sep 22.

PMID:
18809976
96.

Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register.

Petersenn S, Buchfelder M, Reincke M, Strasburger CM, Franz H, Lohmann R, Quabbe HJ, Plöckinger U; Participants of the German Acromegaly Register.

Eur J Endocrinol. 2008 Nov;159(5):525-32. doi: 10.1530/EJE-08-0498. Epub 2008 Aug 28.

PMID:
18755874
97.

Lipodystrophy in patients with acromegaly receiving pegvisomant.

Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S.

J Clin Endocrinol Metab. 2008 Sep;93(9):3515-8. doi: 10.1210/jc.2008-0833. Epub 2008 Jul 8.

PMID:
18611977
98.

Lymph node gastrinoma in multiple endocrine neoplasia type 1 - a diagnostic challenge.

Müssig K, Wehrmann M, Horger M, Bares R, Häring HU, Gallwitz B, Petersenn S.

Exp Clin Endocrinol Diabetes. 2008 Oct;116(9):554-7. doi: 10.1055/s-2008-1062727. Epub 2008 Apr 1.

PMID:
18523912
99.

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M.

J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62. doi: 10.1210/jc.2007-2734. Epub 2008 Apr 15. Review.

100.

Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.

Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K.

Horm Metab Res. 2008 Mar;40(3):210-3. doi: 10.1055/s-2008-1046781.

PMID:
18348081
101.

Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia.

Walz MK, Gwosdz R, Levin SL, Alesina PF, Suttorp AC, Metz KA, Wenger FA, Petersenn S, Mann K, Schmid KW.

World J Surg. 2008 May;32(5):847-53. doi: 10.1007/s00268-008-9513-0.

PMID:
18343972
102.

Differential expression of ghrelin and its receptor (GHS-R1a) in various adrenal tumors and normal adrenal gland.

Ueberberg B, Unger N, Sheu SY, Walz MK, Schmid KW, Saeger W, Mann K, Petersenn S.

Horm Metab Res. 2008 Mar;40(3):181-8. doi: 10.1055/s-2007-1004574. Epub 2008 Feb 4.

PMID:
18246525
103.

Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.

Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S.

J Clin Endocrinol Metab. 2008 Apr;93(4):1203-10. doi: 10.1210/jc.2007-1986. Epub 2008 Jan 15.

PMID:
18198230
104.

Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours.

Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Saeger W, Schmid KW, Mann K, Petersenn S.

Clin Endocrinol (Oxf). 2008 Jun;68(6):850-7. Epub 2007 Nov 19.

PMID:
18031328
105.

Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.

Müssig K, Petersenn S, Wehrmann M, Horger M, Vierling P, Häring HU, Gallwitz B.

Eur J Gastroenterol Hepatol. 2007 Aug;19(8):719-23.

PMID:
17625444
106.

Characterization and transcriptional regulation of the human somatostatin receptor subtype 1 gene.

Redmann A, Rasch A, Tourné H, Mann K, Petersenn S.

Horm Metab Res. 2007 May;39(5):359-65.

PMID:
17533578
107.

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group.

Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68. Epub 2007 Apr 25.

108.

Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.

Müssig K, Gallwitz B, Honegger J, Strasburger CJ, Bidlingmaier M, Machicao F, Bornemann A, Ranke MB, Häring HU, Petersenn S.

Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):198-202.

PMID:
17427111
109.

[Leydig cell tumor as a cause of hirsutism in a postmenopausal woman].

Matuszczyk A, Petersenn S, Lahner H, Haude M, Veit P, Becker JU, Kimmig R, Bockisch A, Mann K.

Med Klin (Munich). 2007 Mar 15;102(3):259-62. German.

PMID:
17345023
110.

Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S.

Eur J Endocrinol. 2007 Feb;156(2):203-16. Review.

PMID:
17287410
111.

The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome.

Hauffa BP, Haase K, Range IM, Unger N, Mann K, Petersenn S.

J Clin Endocrinol Metab. 2007 Mar;92(3):834-40. Epub 2006 Dec 27.

PMID:
17192298
112.

Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients.

Walz MK, Alesina PF, Wenger FA, Deligiannis A, Szuczik E, Petersenn S, Ommer A, Groeben H, Peitgen K, Janssen OE, Philipp T, Neumann HP, Schmid KW, Mann K.

Surgery. 2006 Dec;140(6):943-8; discussion 948-50.

PMID:
17188142
113.

The German Acromegaly Registry: description of the database and initial results.

Reincke M, Petersenn S, Buchfelder M, Gerbert B, Skrobek-Engel G, Franz H, Lohmann R, Quabbe HJ.

Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):498-505.

PMID:
17115347
114.

Diagnostic value of biochemical parameters in the differential diagnosis of an adrenal mass.

Petersenn S, Unger N, Walz MK, Mann K.

Ann N Y Acad Sci. 2006 Aug;1073:348-57. Review.

PMID:
17102104
115.

Gadolinium as an alternative contrast agent during cardiac catheterization in patient with iodine-induced hyperthyroidism.

Matuszczyk A, Hahn S, Böse D, Eggebrecht H, Schmermund A, Quadbeck B, Wieneke H, Petersenn S, Janssen OE, Mann K.

Exp Clin Endocrinol Diabetes. 2006 Jun;114(6):336-8.

PMID:
16868894
116.

[Diagnosis and therapy of endocrine hypertension].

Unger N, Petersenn S, Mann K.

Med Klin (Munich). 2006 Mar 22;101 Suppl 1:170-2. German.

PMID:
16802547
117.

Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery.

Fasshauer M, Lincke T, Witzigmann H, Kluge R, Tannapfel A, Moche M, Buchfelder M, Petersenn S, Kratzsch J, Paschke R, Koch CA.

BMC Cancer. 2006 Apr 27;6:108.

118.

Efficacy and limits of somatostatin analogs.

Petersenn S.

J Endocrinol Invest. 2005;28(11 Suppl International):53-7. Review.

PMID:
16625846
119.

Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients.

Walz MK, Alesina PF, Wenger FA, Koch JA, Neumann HP, Petersenn S, Schmid KW, Mann K.

World J Surg. 2006 May;30(5):899-908.

PMID:
16617419
120.

Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass.

Unger N, Pitt C, Schmidt IL, Walz MK, Schmid KW, Philipp T, Mann K, Petersenn S.

Eur J Endocrinol. 2006 Mar;154(3):409-17.

PMID:
16498054
121.

Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury.

Schneider HJ, Schneider M, Saller B, Petersenn S, Uhr M, Husemann B, von Rosen F, Stalla GK.

Eur J Endocrinol. 2006 Feb;154(2):259-65.

PMID:
16452539
122.

Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland.

Ueberberg B, Tourne H, Redmann A, Walz MK, Schmid KW, Mann K, Petersenn S.

Horm Metab Res. 2005 Dec;37(12):722-8. Erratum in: Horm Metab Res. 2006 Sep;38(9):617. Redman, A [corrected to Redmann, A].

PMID:
16372224
123.

Salivary cortisol measurement--a reliable method for the diagnosis of Cushing's syndrome.

Trilck M, Flitsch J, Lüdecke DK, Jung R, Petersenn S.

Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):225-30. Erratum in: Exp Clin Endocrinol Diabetes. 2005 Jul;113(7):409.

PMID:
15891959
124.

Endoscopic treatment of large primary adrenal tumours.

Walz MK, Petersenn S, Koch JA, Mann K, Neumann HP, Schmid KW.

Br J Surg. 2005 Jun;92(6):719-23.

PMID:
15856491
125.

Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors.

Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Schmid KW, Mann K, Petersenn S.

Endocr Res. 2004 Nov;30(4):931-4.

PMID:
15666847
126.

Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias.

Walz MK, Peitgen K, Diesing D, Petersenn S, Janssen OE, Philipp T, Metz KA, Mann K, Schmid KW, Neumann HP.

World J Surg. 2004 Dec;28(12):1323-9. Epub 2004 Nov 11.

PMID:
15517476
127.

Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass.

Unger N, Lopez Schmidt I, Pitt C, Walz MK, Philipp T, Mann K, Petersenn S.

Eur J Endocrinol. 2004 Apr;150(4):517-23.

PMID:
15080782
129.

Structure and regulation of the growth hormone secretagogue receptor.

Petersenn S.

Minerva Endocrinol. 2002 Dec;27(4):243-56. Review.

PMID:
12511847
130.
131.

Identification of an upstream pituitary-active promoter of human somatostatin receptor subtype 5.

Petersenn S, Rasch AC, Böhnke C, Schulte HM.

Endocrinology. 2002 Jul;143(7):2626-34.

PMID:
12072395
133.

Characterization of the human somatostatin receptor type 4 promoter.

Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM.

Mol Cell Endocrinol. 2002 Feb 25;188(1-2):75-83.

PMID:
11911948
134.

Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor.

Petersenn S, Rasch AC, Penshorn M, Beil FU, Schulte HM.

Endocrinology. 2001 Jun;142(6):2649-59.

PMID:
11356716
135.

Differentiation and regulation of the corticotropic pituitary cell.

Petersenn S, Schulte HM.

Eur J Clin Invest. 2000 Dec;30 Suppl 3:10-3. Review.

PMID:
11281361
136.

Structure and function of the growth-hormone-releasing hormone receptor.

Petersenn S, Schulte HM.

Vitam Horm. 2000;59:35-69. Review.

PMID:
10714236
137.

Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas.

Petersenn S, Heyens M, Lüdecke DK, Beil FU, Schulte HM.

Clin Endocrinol (Oxf). 2000 Jan;52(1):35-42.

PMID:
10651751
138.

Genomic structure and transcriptional regulation of the human somatostatin receptor type 2.

Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM.

Mol Cell Endocrinol. 1999 Nov 25;157(1-2):75-85.

PMID:
10619399
139.

[Molecular analysis of the human "growth hormone secretagogue"-receptor].

Petersenn S, Penshorn M, Beil FU, Schulte HM.

Med Klin (Munich). 1999 Apr 15;94(4):202-6. German.

PMID:
10373755
140.

Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.

Chen C, Farnworth P, Petersenn S, Musgrave I, Canny BJ, Clarke IJ.

Endocrine. 1998 Aug;9(1):71-7.

PMID:
9798733
141.

Structure and regulation of the human growth hormone-releasing hormone receptor gene.

Petersenn S, Rasch AC, Heyens M, Schulte HM.

Mol Endocrinol. 1998 Feb;12(2):233-47.

PMID:
9482665
142.

Transcriptional activation of the human growth hormone gene by ras oncogene.

Petersenn S, Maaser C, Schulte HM.

Mol Cell Endocrinol. 1997 Apr 25;129(1):47-54.

PMID:
9175628
143.

Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure.

Meissner A, Petersenn S, Heidemann HT, Osterkamp U, Simon R, Schulte HM.

Klin Wochenschr. 1991 Mar 18;69(5):213-9.

PMID:
2033915

Supplemental Content

Loading ...
Support Center